PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,641,069 | +2.4% | 68,454 | +12.2% | 0.03% | 0.0% |
| Q2 2022 | $3,556,300 | -19.4% | 61,000 | -22.5% | 0.03% | -6.2% |
| Q3 2021 | $4,410,280 | +65.6% | 78,755 | +107.2% | 0.03% | +33.3% |
| Q1 2021 | $2,663,420 | -58.9% | 38,000 | -64.9% | 0.02% | -52.9% |
| Q4 2020 | $6,485,818 | +261.5% | 108,386 | +263.3% | 0.05% | +155.0% |
| Q3 2020 | $1,794,000 | +74.5% | 29,836 | +52.2% | 0.02% | +66.7% |
| Q2 2020 | $1,028,000 | -93.8% | 19,600 | -96.0% | 0.01% | -93.5% |
| Q1 2020 | $16,598,000 | +3998.3% | 494,993 | +4554.4% | 0.18% | +6033.3% |
| Q3 2019 | $405,000 | -92.1% | 10,635 | -91.0% | 0.00% | -91.9% |
| Q2 2019 | $5,111,000 | +151.0% | 117,535 | +119.8% | 0.04% | +131.2% |
| Q1 2019 | $2,036,000 | -48.7% | 53,481 | -42.1% | 0.02% | -50.0% |
| Q4 2018 | $3,972,000 | -45.3% | 92,337 | -37.5% | 0.03% | -31.9% |
| Q3 2018 | $7,258,000 | +962.7% | 147,656 | +593.4% | 0.05% | +1075.0% |
| Q2 2018 | $683,000 | +45.3% | 21,296 | +106.7% | 0.00% | +100.0% |
| Q4 2017 | $470,000 | -5.4% | 10,303 | -22.2% | 0.00% | -33.3% |
| Q3 2017 | $497,000 | -57.1% | 13,242 | -45.5% | 0.00% | -62.5% |
| Q2 2017 | $1,159,000 | -20.8% | 24,294 | -24.3% | 0.01% | -27.3% |
| Q1 2017 | $1,463,000 | +106.3% | 32,081 | +54.8% | 0.01% | +175.0% |
| Q3 2016 | $709,000 | -8.6% | 20,721 | -9.9% | 0.00% | 0.0% |
| Q2 2016 | $776,000 | +192.8% | 23,007 | +360.1% | 0.00% | +100.0% |
| Q1 2016 | $265,000 | -90.1% | 5,000 | -85.7% | 0.00% | -86.7% |
| Q4 2015 | $2,688,000 | +695.3% | 35,000 | +326.8% | 0.02% | +650.0% |
| Q3 2015 | $338,000 | -14.6% | 8,200 | +46.4% | 0.00% | 0.0% |
| Q2 2015 | $396,000 | -92.6% | 5,600 | -90.7% | 0.00% | -93.3% |
| Q1 2015 | $5,340,000 | +453.4% | 60,100 | +472.4% | 0.03% | +275.0% |
| Q2 2014 | $965,000 | -82.2% | 10,500 | -86.4% | 0.01% | -84.9% |
| Q1 2014 | $5,409,000 | +1358.0% | 77,283 | +902.6% | 0.05% | +1225.0% |
| Q3 2013 | $371,000 | -47.9% | 7,708 | -68.6% | 0.00% | -50.0% |
| Q2 2013 | $712,000 | – | 24,535 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |